Heritage Oak Wealth Advisors LLC Raises Stock Position in Eli Lilly and Company (NYSE:LLY)

Heritage Oak Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 109.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 860 shares of the company’s stock after buying an additional 450 shares during the quarter. Heritage Oak Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $762,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Lynx Investment Advisory bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $32,000. LGT Financial Advisors LLC bought a new stake in Eli Lilly and Company in the second quarter worth about $36,000. Cedar Mountain Advisors LLC boosted its position in shares of Eli Lilly and Company by 53.3% during the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after buying an additional 16 shares during the period. Morton Brown Family Wealth LLC grew its stake in shares of Eli Lilly and Company by 45.5% during the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after buying an additional 15 shares during the last quarter. Finally, Unique Wealth Strategies LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $45,000. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LLY. Berenberg Bank increased their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Finally, Truist Financial boosted their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,013.41.

Eli Lilly and Company Trading Up 0.2 %

NYSE:LLY opened at $892.70 on Friday. The firm has a 50 day moving average of $919.74 and a 200 day moving average of $862.48. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The stock has a market capitalization of $848.45 billion, a price-to-earnings ratio of 109.94, a PEG ratio of 3.24 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 14.05 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.